drugset / Trial / NCT06802835
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Phase 1/2
Recruiting
148 enrolled
Sun Yat-sen University
Chongqing University Cancer Hospital · collabDongguan People's Hospital · collabFirst Affiliated Hospital of Guangxi Medical University · collabFujian Province Tumor Hospital · collabJiangxi Provincial Cancer Hospital · collabLiuzhou Workers' Hospital · collabSecond Affiliated Hospital, School of Medicine, Zhejiang University · collabWuhan TongJi Hospital · collabXijing hospital of The fourth military medical university · collabZhejiang Cancer Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single-arm, phase II clinical trial. The purpose of this study is to evaluate the efficacy and adverse effect of EGFR antibody combined with programmed death 1 (PD-1) antibody and chemotherapy in recurrent/metastatic nasopharyngeal carcinoma patients.
Timeline
- Start
- 2025-07-09
- Primary completion
- 2027-06
- Completion
- 2029-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | — | — |
| Subject | Gemcitabine | Small molecule | — | — |